Observation Study of Sequential Regorafenib Combined With Immunocheckpoint Inhibitors After Hepatic Artery Infusion Chemotherapy for Advanced Hepatocellular Carcinoma
Latest Information Update: 21 Oct 2022
At a glance
- Drugs Atezolizumab (Primary) ; Camrelizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Regorafenib (Primary) ; Sintilimab (Primary) ; Tislelizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 21 Oct 2022 New trial record